Clinical trials: Hyperuricemia
Hyperuricemia
Rasburicase in Tumor Lysis Syndrome
The purpose of this study is to determine whether rasburicase is effective and safety in correcting hyperuricemia.
- Trial name
- NCT00302653
- Testing
- Rasburicase
- Where
- Brazil
- Volunteers
- 33 people
- Sponsor
- Sanofi
Nutritional and Metabolic Diseases
Rasburicase for Hyperuricemia
Primary: To estimate efficacy of SR29142 to the pediatric patients with newly diagnosed hematological malignancies at high risk for Tumor Lysis Syndrome, by evaluation of plasma uric acid concentration.
- Trial name
- NCT00290992
- Testing
- rasburicase (SR29142)
- Where
- Japan
- Volunteers
- 30 people
- Sponsor
- Sanofi
Tumors, Hyperuricemia
Study of Rasburicase as Treatment or Prevention of Hyperuricemia Associated With Tumor Lysis Syndrome in Patients With Relapsed or Refractory Lymphoma, Leukemia, or Solid Tumor Malignancy
This is an open-label, multi-center study with 2 arms. The primary objective is to assess the response to treatment with rasburicase in 2 populations of adult and pediatric patients with lymphoma/leukemia/solid tumor…
- Conditions
- Tumors, Hyperuricemia, Tumor Lysis Syndrome
- Trial name
- NCT00230217
- Testing
- Rasburicase (SR29142)
- Where
- 7 sites in United States
- Volunteers
- 94 people
- Sponsor
- Sanofi
Hyperuricemia
Rasburicase for Treatment of Hyperuricemia in Children and Adolescence Patients With Tumor Lysis Syndrome
To provide treatment opportunity to children and adolescent patients with hematologic malignancies by supplying the delayed marketed product and also to observe the efficacy and safety of rasburicase used in the treatment of…
- Trial name
- NCT00563771
- Testing
- Rasburicase
- Where
- South Korea
- Volunteers
- 38 people
- Sponsor
- Sanofi
Hyperuricemia
Safety and Efficacy of TULY (Rasburicase) in Prevention and Treatment of Malignancy-associated Hyperuricemia
This study is a prospective, open-label, multicentre study. Hundred eligible patients with stage III or IV non-Hodgkin lymphoma (NHL) or acute lymphoblastic leukemia (ALL) with a peripheral white blood cell (WBC) count of >…
- Trial name
- NCT00921375
- Testing
- TULY
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Virchow Group
Lymphoma
Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia
Primary Objective: To evaluate safety of rasburicase in pediatric patients with NHL and AL Secondary Objective: To assess efficacy of rasburicase for prevention and treatment of hyperuricemia
- Trial name
- RAISE (NCT04349306)
- Testing
- RASBURICASE SR29142
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sanofi